Haemonetics Corporation
HAE
Pozycja w akcjach
#3283
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Cena akcji
$118.27
Kapitalizacja rynkowa
$5.38B
Zmiana (1 dzień)
-0.19%
Zmiana (1 rok)
133.23%
Kraj
US
Handel Haemonetics Corporation (HAE)
Kategoria
Healthcare
Wskaźnik P/E dla Haemonetics Corporation (HAE)
Wskaźnik P/E na dzień October 2026 TTM: 58.79
Według najnowszych raportów finansowych i ceny akcji Haemonetics Corporation, obecny wskaźnik P/E (TTM) wynosi 58.79. Na koniec 2024 wskaźnik P/E wynosił 36.57.
Historia wskaźnika P/E dla Haemonetics Corporation od 2000 do 2026
Wskaźnik P/E na koniec każdego roku
| Rok | Wskaźnik P/E | Zmień |
|---|---|---|
| 2026 (TTM) | 58.79 | 209.92% |
| 2025 | 18.97 | -48.14% |
| 2024 | 36.57 | 0.43% |
| 2023 | 36.41 | -51.54% |
| 2022 | 75.14 | 5.15% |
| 2021 | 71.46 | 6.87% |
| 2020 | 66.87 | -18.39% |
| 2019 | 81.94 | -3.25% |
| 2018 | 84.69 | -206.46% |
| 2017 | -79.55 | 146.27% |
| 2016 | -32.30 | -123.96% |
| 2015 | 134.83 | 185.97% |
| 2014 | 47.15 | -14.48% |
| 2013 | 55.13 | 108.66% |
| 2012 | 26.42 | 26.60% |
| 2011 | 20.87 | -15.24% |
| 2010 | 24.62 | 5.04% |
| 2009 | 23.44 | -19.61% |
| 2008 | 29.16 | 14.54% |
| 2007 | 25.46 | 30.83% |
| 2006 | 19.46 | -27.03% |
| 2005 | 26.67 | 2.01% |
| 2004 | 26.14 | 34.39% |
| 2003 | 19.45 | -29.80% |
| 2002 | 27.71 | -76.06% |
| 2001 | 115.73 | 274.57% |
| 2000 | 30.90 | 0.00% |
Wskaźnik P/E dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/E | Różnica wskaźnika P/E | Kraj |
|---|---|---|---|
| 33.11 | -43.68% |
US
|
|
| 21.39 | -63.62% |
IE
|
|
| 28.94 | -50.77% |
US
|
|
| 17.34 | -70.51% |
US
|
|
| - | - |
DE
|
Jak odczytywać wskaźnik P/E?
Wskaźnik Cena/Zysk (P/E) mierzy relację między ceną akcji firmy a jej zyskiem na akcję.
Niski, ale dodatni P/E oznacza firmę osiągającą wysokie zyski względem obecnej wyceny i może być niedowartościowana. Wysoki ujemny (bliski 0) P/E wskazuje na duże straty.
Firmy z P/E powyżej 30 lub ujemnym uznaje się zazwyczaj za "akcje wzrostowe", czyli inwestorzy oczekują wzrostu lub przyszłych zysków.
Firmy z dodatnim P/E poniżej 10 uznaje się za "akcje wartościowe", co oznacza, że są już bardzo dochodowe, ale bez dużego potencjału wzrostu.